Last Name

 First Name

 email

 

MEDICAL PROFESSIONALS

Extensive World Health Organization (WHO) standardized Clinical Trials have shown that Flu-STOP™ inactivates the HA and NA on several viruses. Flu-STOP™ is made from 5 kinds of traditional Chinese herbs using ultra-modern extraction technology. (all data is summarized below)

The result of almost five years of extensive clinical research & development, Flu-STOP™ is a highly effective, natural, herbal, over-the-counter (OTC), oral anti-flu spray and is a patented scientific formulation. Developed by Professor D.S. Liu, Ph.D., one of China's most eminent and respectable virologists, Flu-STOP™ began originally as an anti-SARS virus drug during the SARS epidemic in 2003. Due to its strong ant-viral properties the product was successfully used to treat SARS infected patients and prevented SARS infection and spread at several hospitals in China.

Product Safety

Long and short term animal toxicity studies conducted on the product confirm Flu-STOP™ to be safe even at 500 times the recommended human dosage. Additionally, the product has been used by over 1,000 volunteers and has been shown to be safe and highly effective.

Invivo tests

In a managed clinical study with patients who used Flu-STOP™, 82.9% had their symptoms disappear in three days or less. Furthermore, Invitro toxicity studies confirmed that Flu-STOP™ is safe.

Scientific Studies

Flu-STOP™ has undergone numerous scientific studies and animal and human clinical trials, based on strict and rigorous pharmaceutical and WHO protocols. These studies demonstrate and confirm that Flu-STOP™ innactivates both Influenza A & B viruses upon contact, thus preventing contraction of the flu* and, further preventing the replication of both Influenza A & B viruses.

A summary of some of these studies and clinical trials is presented below: A 153 patient placebo-controlled clinical trial of patients with Upper Respiratory Tract Infection demonstrated an 82.9% three day recovery rate in the Flu-STOP™ group compared to 19.6% in the placebo (untreated) control group (see chart below).

Viral Respiratory Tract Infection Patients Using Flu-STOP™
(82 patients)

Day --> 1 2 3 4 5 6 7
Patients Recovered
31
30
7
6
3
3
2
% Patients Recovered
37.8%
36.6%
8.5%
7.3%
3.8%
3.6%
2.4%


Viral Respiratory Tract Infection Patients Using Placebo
(71 patients)

Day --> 1 2 3 4 5 6 7
Patients Recovered
0
5
9
31
20
3
3
% Patients Recovered
0%
7%
12.6%
43.7%
28.1%
4.3%
4.3%

Notes:
1. Viral Respiratory Tract Infection includes the common cold and anginosis, etc.
2. Clinical trial patients were aged 6 to 72, with 79 males and 75 females.


FluStop Interferon Effectiveness Comparison
Comparative in-vivo studies on sixty Influenza-induced mice confirm Flu-STOP™’s superiority to Interferon (a leading anti-viral pharmaceutical) against the Influenza virus, offering a protection rate of 55%, compared to only 40% for Interferon, and 10% for the non-treated, control group.

Anti-Bacteria
In-vivo bacteriological screening of Flu-STOP™ against the three bacterial strains known to commonly infect the human respiratory tract - H.influenza, Aureus staphylococcus and A-hemolytic streptococcus confirmed the Flu-STOP™ compound (at 45% concentration) inhibited these bacterial strains in comparison to both positive (Penicillin) and negative (NaCl) control groups.

Note: H.influenza is the main cause of epidemic meningitis.

Acute Toxicity Experiment With Mice

Flu-STOP™ was sprayed to the oral and nasal cavity of mice to test toxicity.

No mice died during the experiment period. The LD50 could not be found at the designed dose. The dose to mice of this experiment was 500 times the human clinical dose. Because the LD50 could not be found, clinical use of the spray is safe to human beings.

Long Term Animal Toxicity Experiment

During the spraying period (including 2 weeks after the 4 weeks continuous spraying), there were no obvious changes of rats’ apparent activities, bite and sup, drinking habits, weight (increasing), blood general index, blood biochemical index, viscera index (all indexes are normal), the main viscera pathological tissue , mucosa of oral cavity and mucosa of nasal cavity. These included the maximum dose group (100 times of human dose) and there were no obvious pathological changes as well. The results confirmed the safety of human clinical dose.

Flu-STOP™ Allergy and Local Stimulation Experiments  

Guinea Pig Allergy Test: There were no allergenic symptoms such as scratched noses, coat erection or decompensation on guinea pigs in the Flu-STOP™ group. Meanwhile, allergenic symptoms appeared with the control group at 14 days and 21 days.

Rat Local Stimulation Test: There was no swilling or congestion on rat's mucosa oral and nasal cavity and respiratory tract tissue. The Flu-STOP™ pathological tests were the same as the positive control group Flu-STOP™ has no stimulation to rat's mucosa and nasal cavity and laryngeal trachea.